Skip to main content
. 2014 Nov 19;23(8):1019–1024. doi: 10.1038/ejhg.2014.229

Figure 1.

Figure 1

Effect of the CHRNA7 CNV-3956 on lung function of COPD and survival of lung cancer. (a) The effect of CNV-3956 on pre-FEV1; (b) the effect of CNV-3956 on pre-FVC; (c) the effect of CNV-3956 on annual average decline of pre-FEV1; (d) Kaplan–Meier survival curve for individuals with lung cancer by the CNV-3956 genotypes in the southern Chinese; and (e) Kaplan–Meier survival curve for individuals with lung cancer by the CNV-3956 genotypes in the eastern Chinese. Columns indicate mean and bars indicate SD; Student's t-test was used to test the differences in lung function between the CNV-3956 genotypes, and the log-rank test was used to assess the effect of CNV-3956 on lung cancer survival. As shown, individuals carrying ≥4-copy had a significantly lower pre-FEV1 but not pre-FVC as well as annual average decline of pre-FEV1 than those carrying 2/3-copy in the total population of COPD study. In addition, the median survival time (MST) of lung cancer patients was significantly decreased in the ≥4-copy carriers than in the 2/3-copy carriers.